Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients
Roche agrees to acquire biotech firm Seragon Pharmaceuticals
8:09 AM MDT | July 2, 2014 | Natasha Alperowicz
Pharma major Roche (Basel) announced today that its Genentech subsidiary has entered into a definitive agreement to acquire Seragon Pharmaceuticals (San Diego), a privately held biotechnology company. Genentech, through the acquisition, obtains rights to Seragon’s entire portfolio of investigational, next-generation, oral selective estrogen receptor degraders (SERDs) for potentially treating hormone-receptor-positive breast cancer. Under the terms of the agreement, Genentech will make an upfront cash payment of $725 million plus additional contingent...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee